Hussman Strategic Advisors, Inc. Pacira Bio Sciences, Inc. Transaction History
Hussman Strategic Advisors, Inc.
- $417 Million
- Q1 2024
A detailed history of Hussman Strategic Advisors, Inc. transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Hussman Strategic Advisors, Inc. holds 21,000 shares of PCRX stock, worth $454,860. This represents 0.15% of its overall portfolio holdings.
Number of Shares
21,000
Previous 21,000
-0.0%
Holding current value
$454,860
Previous $708,000
13.42%
% of portfolio
0.15%
Previous 0.16%
Shares
7 transactions
Others Institutions Holding PCRX
# of Institutions
287Shares Held
48.7MCall Options Held
156KPut Options Held
623K-
Black Rock Inc. New York, NY7.91MShares$171 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.11MShares$111 Million0.0% of portfolio
-
Frontier Capital Management CO LLC1.91MShares$41.5 Million0.55% of portfolio
-
State Street Corp Boston, MA1.9MShares$41.2 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.88MShares$40.8 Million0.09% of portfolio
About Pacira BioSciences, Inc.
- Ticker PCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 45,824,200
- Market Cap $993M
- Description
- Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...